{"id":"tazorac-cream-0-1","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Skin irritation (erythema, peeling, dryness)"},{"rate":null,"effect":"Photosensitivity"},{"rate":"10-20","effect":"Burning or stinging sensation"},{"rate":"5-15","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL2108947","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tazarotene is a third-generation topical retinoid that selectively binds to retinoic acid receptors (RARs), particularly RAR-beta and RAR-gamma. This binding modulates gene expression to normalize keratinization, reduce sebum production, and decrease inflammatory mediators in the skin. It is used to treat acne and psoriasis by promoting skin cell turnover and reducing hyperkeratinization.","oneSentence":"Tazarotene is a retinoid that binds to retinoid receptors to regulate cell differentiation and reduce inflammation in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:50.153Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Plaque psoriasis"},{"name":"Photoaging and fine wrinkles"}]},"trialDetails":[{"nctId":"NCT00469755","phase":"PHASE4","title":"Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-02","conditions":"Acne Vulgaris","enrollment":302},{"nctId":"NCT03599193","phase":"PHASE2","title":"A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-10-04","conditions":"Acne Vulgaris","enrollment":58},{"nctId":"NCT00489086","phase":"PHASE2","title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2004-07","conditions":"Neoplastic Syndrome","enrollment":36},{"nctId":"NCT03341910","phase":"PHASE2","title":"A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-08-21","conditions":"Acne Vulgaris","enrollment":155},{"nctId":"NCT00440024","phase":"NA","title":"The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2007-02","conditions":"Sun-Damaged Skin, Retinoid Intolerance","enrollment":40},{"nctId":"NCT02886715","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-21","conditions":"Acne Vulgaris","enrollment":1110},{"nctId":"NCT02411955","phase":"PHASE1","title":"A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-06","conditions":"Acne Vulgaris","enrollment":1077},{"nctId":"NCT01016977","phase":"PHASE4","title":"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT02160678","phase":"PHASE3","title":"Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"G & W Laboratories Inc.","startDate":"2014-05","conditions":"Acne Vulgaris","enrollment":1741},{"nctId":"NCT00783965","phase":"PHASE2","title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2004-07","conditions":"Skin Carcinoma","enrollment":34},{"nctId":"NCT02525822","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris","status":"UNKNOWN","sponsor":"Valeant Pharmaceuticals","startDate":"2015-09","conditions":"Acne Vulgaris","enrollment":210},{"nctId":"NCT02218034","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-08","conditions":"Acne Vulgaris","enrollment":78},{"nctId":"NCT00829049","phase":"PHASE4","title":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-10","conditions":"Acne Vulgaris","enrollment":165},{"nctId":"NCT00834210","phase":"PHASE4","title":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":171},{"nctId":"NCT00779896","phase":"PHASE1, PHASE2","title":"Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study","status":"UNKNOWN","sponsor":"McGill University","startDate":"2008-10","conditions":"Cutaneous T-Cell Lymphoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazarotene Cream, 0.1%","Reference Listed Drug"],"phase":"phase_3","status":"active","brandName":"Tazorac Cream, 0.1%","genericName":"Tazorac Cream, 0.1%","companyName":"Dr. Reddy's Laboratories Limited","companyId":"dr-reddy-s-laboratories-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tazorac Cream, 0.1%, is used to treat conditions such as Skin Carcinoma, Acne Vulgaris, Cutaneous T-Cell Lymphoma, and Neoplastic Syndrome, as indicated by ClinicalTrials.gov. The exact mechanism of action of Tazorac Cream is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}